• Zevra Therapeutics recently disclosed that shareholders at its June 4, 2026 annual meeting rejected an amendment to phase out the company’s classified board structure, which would have shifted all directors to one-year terms beginning with the 2027 annual meeting.
• Around the same time, Zevra moved to strengthen its intellectual property position by asking the U.S. Food and Drug Administration to list a new MIPLYFFA patent in the Orange Book, aiming to extend patent protection to 2041 and reinforce exclusivity for this ultra-rare disease therapy.
• With the company seeking extended MIPLYFFA patent protection, we’ll now examine what this means for Zevra’s investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Zevra Therapeutics' Investment Narrative?

To own Zevra today, you really need to believe in the durability of its newly profitable rare‑disease model, with MIPLYFFA at the center. The attempted move to declassify the board and its rejection keeps a staggered structure in place, which may limit how quickly activist shareholders can influence capital allocation and deal decisions, but likely does not alter near term operational drivers. By contrast, the FDA Orange Book submission for a MIPLYFFA patent out to 2041 speaks directly to Zevra’s core catalyst: protecting the revenue stream from this ultra rare NPC therapy. If the listing is accepted, it could reinforce Zevra’s earnings profile and help support further development, although concentration in a small asset base and high non cash earnings remain key issues to watch.

However, investors should be aware of Zevra’s reliance on MIPLYFFA and non cash earnings quality. Zevra Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community span roughly US$18 to just under US$100 per share, underscoring how differently people view Zevra’s upside. Set against this, the recent MIPLYFFA patent move and the unchanged classified board both feed into how secure future cash flows might be, which is central to how you weigh those divergent views on the company’s prospects. If you are weighing an investment case here, it is worth comparing several of these perspectives side by side.

Explore 10 other fair value estimates on Zevra Therapeutics - why the stock might be worth just $18.00!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zevra Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zevra Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zevra Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 27 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.